Quotient Bioresearch Announce Collaboration with Clinical Reference Laboratory
News Aug 25, 2009
Quotient Bioresearch Limited and Clinical Reference Laboratory have concluded an agreement that will result in the provision of a global clinical laboratory testing capability to support the two Group’s clients world wide.
Under the collaboration, CRL Global Services will set up its European clinical reference laboratory operation within Quotient’s facility in Cambridgeshire, UK, establishing it as the European hub for its Central Laboratory Services unit. This will complement Quotient’s existing clinical laboratory services, particularly in the area of bioanalysis and biomarkers.
Paul Cowan, CEO of Quotient Bioresearch commented: “This collaboration brings exciting new opportunities for our bioanalytical sciences and microbiology businesses. Working in tandem with CRL offers access to a well established, standardized global laboratory infrastructure and the ability to serve the requirements of our clients for global clinical trials.”
Tim Sotos, CEO of Clinical Reference Laboratory added “Quotient Bioresearch is an excellent partner for Clinical Reference Laboratory. Quotient’s strong track record in high quality bioanalytical sciences and early phase drug development is highly complementary to our business and offers significant added value in the provision of central laboratory services.”
Researchers at the University of Arizona have completed the first-of-its-kind study that could aid in the treatment, diagnosis and prevention of cervical cancer by identifying cervicovaginal metabolic signatures, or "fingerprints" that distinguish patients with HPV, pre-cancerous cervical conditions and cancer.READ MORE
Regardless of how much you exercise or how balanced your diet is, controlling your weight is more brain-related than you might have thought. In a recent study, researchers show for the first time in mice that the acyl-CoA-binding protein, or ACBP, has a direct influence on the neurons that allow rodents and humans to maintain a healthy weight.READ MORE
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE